Clinical Trials Browser

Phase 1/2 × Specimen Handling × 30 days × Clear all

NCT05232851 2026-04-14

A Vaccine (PDS0101) Alone or in Combination With Pembrolizumab for the Treatment of Locally Advanced Human Papillomavirus-Associated Oropharynx Cancer

Phase 1/2 Active not recruiting

20 enrolled 11 charts

Carcinoma, Oropharyngeal Neoplasms

NCT06965114 2026-04-14

Testing the Combination of Anti-cancer Drugs, Tovorafenib Plus Rituximab, in Patients With Hairy Cell Leukemia

Phase 1/2 Recruiting

Other hematologic neoplasm

Leukemia, Hairy Cell

NCT01089101 2026-04-13

Selumetinib in Treating Young Patients With Recurrent or Refractory Low Grade Glioma

Phase 1/2 Active not recruiting

Astrocytoma, Neurofibromatosis 1

NCT01989585 2026-04-13

Testing the Addition of Navitoclax to the Combination of Dabrafenib and Trametinib in People Who Have BRAF Mutant Melanoma

Phase 1/2 Active not recruiting

Melanoma

NCT03604978 2026-04-13

Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma

Phase 1/2 Active not recruiting

Meningioma

NCT03831932 2026-04-13

Telaglenastat Hydrochloride and Osimertinib in Treating Patients With EGFR-Mutated Stage IV Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

22 enrolled 12 charts

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT03854474 2026-04-13

Testing the Addition of Tazemetostat to the Immunotherapy Drug, Pembrolizumab (MK-3475), in Advanced Urothelial Carcinoma

Phase 1/2 Active not recruiting

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT04068194 2026-04-13

Testing the Combination of New Anti-cancer Drug Peposertib With Avelumab and Radiation Therapy for Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Phase 1/2 Active not recruiting

Gastrointestinal

Gallbladder Neoplasms, Neoplasm Metastasis, Cholangiocarcinoma

NCT04071236 2026-04-13

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy

Phase 1/2 Recruiting

Lymphatic Metastasis, Prostatic Neoplasms

NCT04172532 2026-04-13

Testing the Addition of a New Anti-cancer Drug, M3814 (Peposertib), to the Usual Radiotherapy in Patients With Locally Advanced Pancreatic Cancer

Phase 1/2 Recruiting

Gastrointestinal

Pancreatic Neoplasms

NCT04216316 2026-04-13

Testing the Addition of an Anti-cancer Drug, Berzosertib (M6620, VX-970), to the Usual Treatments (Carboplatin and Gemcitabine) and to Pembrolizumab for Patients With Advanced Squamous Cell Non-small Cell Lung Cancer

Phase 1/2 Active not recruiting

12 enrolled 25 charts

Lung Neoplasms

NCT04317105 2026-04-13

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Immunotherapy (Nivolumab With or Without Ipilimumab) in Patients With Advanced Solid Cancers That Have Changes in the Following Genes: PIK3CA and PTEN

Phase 1/2 Active not recruiting

Neoplasm Metastasis

NCT04345913 2026-04-13

Testing the Addition of Copanlisib to Eribulin in Metastatic Triple Negative Breast Cancer

Phase 1/2 Active not recruiting

24 enrolled 24 charts

Triple Negative Breast Neoplasms

NCT05019716 2026-04-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

Phase 1/2 Recruiting

Advanced NUT Carcinoma

NCT05286801 2026-04-13

Tiragolumab and Atezolizumab for the Treatment of Relapsed or Refractory SMARCB1 or SMARCA4 Deficient Tumors

Phase 1/2 Active not recruiting

Chordoma, Sarcoma, Rhabdoid Tumor

NCT05432804 2026-04-13

Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment

Phase 1/2 Suspended

Glioblastoma

NCT05538897 2026-04-13

Testing the Addition of the AKT Inhibitor, Ipatasertib, to Treatment With the Hormonal Agent Megestrol Acetate for Recurrent or Metastatic Endometrial Cancers

Phase 1/2 Active not recruiting

FIGO Grade 1 Endometrial Endometrioid Adenocarcinoma

NCT05691491 2026-04-13

Testing the Combination of the Anti-Cancer Drugs Temozolomide and M1774 to Evaluate Their Safety and Effectiveness

Phase 1/2 Recruiting

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT05896839 2026-04-13

Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin Cancer

Phase 1/2 Recruiting

Carcinoma, Basal Cell, Melanoma, Carcinoma, Merkel Cell

NCT06287775 2026-04-13

Testing the Combination of an Anti-cancer Drug, Iadademstat, With Other Anti-cancer Drugs (Atezolizumab or Durvalumab) at Improving Outcomes for Small Cell Lung Cancer

Phase 1/2 Recruiting

Lung Neoplasms

NCT06498648 2026-04-13

Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma

Phase 1/2 Recruiting

Leiomyosarcoma, Liposarcoma, Sarcoma

NCT06616155 2026-04-13

Ruxolitinib and Enzalutamide for the Treatment of Metastatic Castration-Resistant Prostate Cancer

Phase 1/2 Recruiting

Prostatic Neoplasms

NCT06811116 2026-04-13

Testing the Addition of an Anti-cancer Drug, Sapanisertib, to the Usual Chemotherapy Treatment (Cabozantinib) in Metastatic Liver Cell Cancer With a Change in Genes for the Protein β-Catenin, The SAPHIRE Trial

Phase 1/2 Recruiting

Gastrointestinal

Carcinoma, Hepatocellular

NCT07012031 2026-04-13

Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C Mutation

Phase 1/2 Recruiting

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07069699 2026-04-13

Testing the Safety of Anti-Cancer Drug, CX-5461 (Pidnarulex), in Treating Lymphoma With Specific Changes in the MYC Gene

Phase 1/2 Recruiting

Burkitt Lymphoma

NCT07147231 2026-04-13

Testing the Effectiveness of the Anti-cancer Drug Pidnarulex (CX-5461), in Combination With Another Anti-cancer Drug Cemiplimab (REGN2810), in Treating Refractory Microsatellite Stable Colorectal Cancer

Phase 1/2 Recruiting

Gastrointestinal

Colorectal Neoplasms

NCT07463807 2026-04-13

Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

Phase 1/2 Not yet recruiting

Multiple Myeloma

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1/2 Not yet recruiting

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT04726241 2026-04-08

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Phase 1/2 Recruiting

LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Biphenotypic, Acute, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Leukemia, Myelomonocytic, Juvenile

NCT05920798 2026-04-06

FRAPPE

Phase 1/2 Recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06306638 2026-04-06

Interstitial Photodynamic Therapy Following Palliative Radiotherapy in Treating Patients With Inoperable Malignant Central Airway Obstruction

Phase 1/2 Recruiting

Other solid neoplasm

Malignant Solid Neoplasm

NCT07225985 2026-04-03

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

Phase 1/2 Not yet recruiting

Lymphoma, T-Cell

NCT03504644 2026-04-02

Venetoclax and Vincristine in Treating Patients With Relapsed or Refractory T-cell or B-cell Acute Lymphoblastic Leukemia

Phase 1/2 Active not recruiting

40 enrolled 18 charts

LymphoidOther hematologic neoplasm

Burkitt Lymphoma, Precursor B-Cell Lymphoblastic Leukemia-Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

NCT07181941 2026-03-27

Response-Based Dose Reduction of Linvoseltamab in the Treatment of Relapsed, Refractory, or Triple-Class Relapsed/Refractory Multiple Myeloma

Phase 1/2 Recruiting

Multiple Myeloma